Recent chatter on X about Nuvalent, Inc. (NUVL) has centered around the company’s promising developments in cancer therapies, sparking keen interest among investors. Many users have pointed to a recent analysis suggesting significant upside potential, fueling optimism about the biotech firm's future. The discussion also touches on the company's participation in high-profile industry events, which has further amplified attention.
Additionally, a notable insider transaction involving the sale of shares by a top executive has stirred some debate on the platform. While some see this as a potential red flag, others argue it’s a routine financial move and emphasize the strong analyst consensus favoring the stock. This mix of perspectives keeps the conversation dynamic and closely watched by market participants.
Note: This discussion summary was generated from an AI condensation of post data.
Nuvalent, Inc. Insider Trading Activity
Nuvalent, Inc. insiders have traded $NUVL stock on the open market 52 times in the past 6 months. Of those trades, 0 have been purchases and 52 have been sales.
Here’s a breakdown of recent trading of $NUVL stock by insiders over the last 6 months:
- JAMES RICHARD PORTER (President and CEO) has made 0 purchases and 20 sales selling 162,000 shares for an estimated $12,210,613.
- ALEXANDRA BALCOM (Chief Financial Officer) has made 0 purchases and 8 sales selling 67,588 shares for an estimated $5,640,151.
- HENRY E. PELISH (Chief Scientific Officer) has made 0 purchases and 9 sales selling 27,870 shares for an estimated $2,197,971.
- DARLENE NOCI (Chief Development Officer) has made 0 purchases and 15 sales selling 24,000 shares for an estimated $1,850,518.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Nuvalent, Inc. Hedge Fund Activity
We have seen 121 institutional investors add shares of Nuvalent, Inc. stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,350,000 shares (-7.0%) from their portfolio in Q2 2025, for an estimated $103,005,000
- JPMORGAN CHASE & CO added 1,095,196 shares (+1073.8%) to their portfolio in Q2 2025, for an estimated $83,563,454
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 643,794 shares (+142.8%) to their portfolio in Q2 2025, for an estimated $49,121,482
- LOGOS GLOBAL MANAGEMENT LP removed 500,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $38,150,000
- JANUS HENDERSON GROUP PLC added 472,385 shares (+36.1%) to their portfolio in Q2 2025, for an estimated $36,042,975
- BOXER CAPITAL MANAGEMENT, LLC removed 450,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $34,335,000
- MARSHALL WACE, LLP removed 360,027 shares (-85.4%) from their portfolio in Q2 2025, for an estimated $27,470,060
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Nuvalent, Inc. Analyst Ratings
Wall Street analysts have issued reports on $NUVL in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 09/08/2025
- Raymond James issued a "Outperform" rating on 09/03/2025
- Piper Sandler issued a "Overweight" rating on 08/19/2025
- Baird issued a "Outperform" rating on 06/25/2025
- Leerink Partners issued a "Outperform" rating on 06/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/24/2025
To track analyst ratings and price targets for Nuvalent, Inc., check out Quiver Quantitative's $NUVL forecast page.
Nuvalent, Inc. Price Targets
Multiple analysts have issued price targets for $NUVL recently. We have seen 7 analysts offer price targets for $NUVL in the last 6 months, with a median target of $115.0.
Here are some recent targets:
- David Nierengarten from Wedbush set a target price of $115.0 on 09/08/2025
- Brad Canino from Guggenheim set a target price of $122.0 on 09/04/2025
- Chris Raymond from Raymond James set a target price of $105.0 on 09/03/2025
- Kelsey Goodwin from Piper Sandler set a target price of $112.0 on 08/19/2025
- Colleen Kusy from Baird set a target price of $112.0 on 06/25/2025
- Andrew Berens from Leerink Partners set a target price of $140.0 on 06/24/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $130.0 on 06/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
